Cederquist represents a syndicate of lenders in connection with MUSD 1,000 financing for Swedish Orphan Biovitrum AB (publ)
Cederquist has represented a syndicate of banks consisting of BNP Paribas, Danske Bank, Skandinaviska Enskilda Banken and Svenska Handelsbanken in connection with Swedish Orphan Biovitrum AB (publ)’s acquisition from AstraZeneca of the rights to Synagis® (palivizumab) in the US and as used for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus.The acquisition also includes certain rights to share in future profits that may arise from a potential new medicine (MEDI8897). The initial purchase price amounts to 1,500 MUSD and is made up by (i)